company background image
61N1 logo

StageZero Life Sciences DB:61N1 Stock Report

Last Price

€0.015

Market Cap

€3.4m

7D

-26.2%

1Y

-75.2%

Updated

21 Mar, 2024

Data

Company Financials

StageZero Life Sciences Ltd.

DB:61N1 Stock Report

Market Cap: €3.4m

61N1 Stock Overview

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe.

61N1 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

StageZero Life Sciences Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for StageZero Life Sciences
Historical stock prices
Current Share PriceCA$0.015
52 Week HighCA$0.065
52 Week LowCA$0.015
Beta0.29
1 Month Change-31.11%
3 Month Change-13.89%
1 Year Change-75.20%
3 Year Change-98.23%
5 Year Change-97.67%
Change since IPO-98.32%

Recent News & Updates

Recent updates

Shareholder Returns

61N1DE BiotechsDE Market
7D-26.2%0.06%0.07%
1Y-75.2%28.6%4.9%

Return vs Industry: 61N1 underperformed the German Biotechs industry which returned 28.6% over the past year.

Return vs Market: 61N1 underperformed the German Market which returned 4.9% over the past year.

Price Volatility

Is 61N1's price volatile compared to industry and market?
61N1 volatility
61N1 Average Weekly Movement32.4%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 61N1's share price has been volatile over the past 3 months.

Volatility Over Time: 61N1's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a40James Howard-Tripphttps://www.stagezerolifesciences.com

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood.

StageZero Life Sciences Ltd. Fundamentals Summary

How do StageZero Life Sciences's earnings and revenue compare to its market cap?
61N1 fundamental statistics
Market cap€3.36m
Earnings (TTM)-€11.54m
Revenue (TTM)€2.65m

1.4x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
61N1 income statement (TTM)
RevenueUS$2.88m
Cost of RevenueUS$2.85m
Gross ProfitUS$29.99k
Other ExpensesUS$12.56m
Earnings-US$12.53m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.10
Gross Margin1.04%
Net Profit Margin-434.85%
Debt/Equity Ratio-15.0%

How did 61N1 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.